An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection

Journal of the National Cancer Institute

Volumn 103, Issue 6, 2011, Pages 462-469

  Vickers, Andrew J ^a   Till, Cathee ^b   Tangen, Catherine M ^b   Lilja, Hans ^a   Thompson, Ian M ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PREVENTION; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIGITAL RECTAL EXAMINATION; DISEASE SEVERITY; FAMILY HISTORY; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; SENSITIVITY AND SPECIFICITY;

AGED; AREA UNDER CURVE; BIOPSY; DIGITAL RECTAL EXAMINATION; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; UNNECESSARY PROCEDURES;

EID: 79952833310     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr028     Document Type: Article

References (25)

1. Burgers JS, Fervers B, Haugh M, et al. International assessment of the quality of clinical practice guidelines in oncology using the Appraisal of Guidelines and Research and Evaluation Instrument. J Clin Oncol. 2004;22(10):2000-7. (Pubitemid 41095193)
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer Early Detection. http://www.nc cn.org/ professionals/physician-gls/PDF/prostate-detection.pdf. Accessed February 3, 2010.
3. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320-1328.
4. Thompson IM, Ankerst DP, Chi C, et al. Operating characteristics of prostate-specifc antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA. 2005;294(1):66-70. (Pubitemid 41002840)
5. Vickers AJ, Cronin AM, Aus G, et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Med. 2008;6:19.
6. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
7. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005;352(19): 1977-1984. (Pubitemid 40638368)
8. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302(11): 1202-1209.
9. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98(8):529-534. (Pubitemid 43898816)
10. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specifc antigen velocity during a window of curability. J Natl Cancer Inst. 2006;98(21):1521-1527. (Pubitemid 44680903)
11. Ulmert D, Serio AM, O'Brien MF, et al. Long-term prediction of prostate cancer: prostate-specifc antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. J Clin Oncol. 2008;26(6):835-841. (Pubitemid 351398073)
12. Ulmert D, Cronin AM, Bjork T, et al. Prostate-specifc antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med. 2008;6:6.
13. Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specifc antigen best practice statement: 2009 update. J Urol. 2009;182(5):2232-2241.
14. Thompson IM, Goodman PJ, Tangen CM, et al. The infuence of fnas-teride on the development of prostate cancer. N Engl J Med. 2003;349(3): 215-224. (Pubitemid 36859473)
15. Goodman PJ, Tangen CM, Crowley JJ, et al. Implementation of the Prostate Cancer Prevention Trial (PCPT). Control Clin Trials. 2004;25(2): 203-222. (Pubitemid 38328759)
16. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical fndings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271(5):368-374. (Pubitemid 24037911)
17. Carter HB, Kettermann A, Ferrucci L, Landis P, Metter EJ. Prostate-specifc antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. Urology. 2007;70(4):685-690. (Pubitemid 350030209)
18. Vickers AJ, Savage C, O'Brien MF, Lilja H. Systematic review of pretreat-ment prostate-specifc antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol. 2009;27(3):398-403.
19. Roobol MJ, Kranse R, de Koning HJ, Schroder FH. Prostate-specifc antigen velocity at low prostate-specifc antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology. 2004;63(2):309-313. (Pubitemid 38234425)
20. Wolters T, Roobol MJ, Bangma CH, Schroder FH. Is prostate-specifc antigen velocity selective for clinically signifcant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam). Eur Urol. 2009;55(2):385-392.
21. Eggener SE, Yossepowitch O, Roehl KA, Loeb S, Yu X, Catalona WJ. Relationship of prostate-specifc antigen velocity to histologic fndings in a prostate cancer screening program. Urology. 2008;71(6): 1016-1019.
22. Vickers AJ, Wolters T, Savage CJ, et al. Prostate-specifc antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol. 2009;56(5):753-760.
23. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351(2):125-135.
24. O'Brien MF, Cronin AM, Fearn PA, et al. Pretreatment prostate-specifc antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol. 2009; 27(22):3591-3597.
25. Nanda A, Chen MH, D'Amico AV. Mathematical rigor is necessary, but for men with prostate cancer, clinical relevance is the priority. J Clin Oncol. 2009;27(10):1728-1729.